Oncolytic enteroviruses

Molecular Biology

Volumn 46, Issue 5, 2012, Pages 639-650

  Chumakov, P M ^a,b,c   Morozova, V V ^a,d   Babkin, I V ^a,d   Baikov, I K ^a,d   Netesov, S V ^a,e   Tikunova, N V ^a,d  

^a NOVOSIBIRSK STATE UNIVERSITY   (Russian Federation)

^b ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^c LERNER RESEARCH INSTITUTE   (United States)

^d INSTITUTE OF CHEMICAL BIOLOGY AND FUNDAMENTAL MEDICINE   (Russian Federation)

^e STATE RESEARCH CENTER OF VIROLOGY AND BIOTECHNOLOGY VECTOR   (Russian Federation)

Author keywords

Coxsackieviruses; Echoviruses; oncolytic enteroviruses; Polioviruses; viral cancer therapy

Indexed keywords

EID: 84867301625     PISSN: 00268933     EISSN: 16083245     Source Type: Journal    
DOI: 10.1134/S0026893312050032     Document Type: Review

References (115)

1. Bernier J., Hall E. J., Giaccia A. 2004. Radiation oncology: A century of achievements. Nature Rev. Cancer. 4, 737-747.
2. Farber S., Diamond L. K. 1948. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N. Engl. J. Med. 238, 787-793.
3. Pui C. H., Robison L. L., Look A. T. 2008. Acute lymphoblastic leukaemia. Lancet. 371, 1030-1043.
4. Bianchini C., Ciorba A., Pelucchi S., Piva R., Pastore A. 2011. Targeted therapy in head and neck cancer. Tumori. 97, 137-141.
5. Litzow M. R. 2011. Pharmacotherapeutic advances in the treatment of acute lymphoblastic leukaemia in adults. Drugs. 71, 415-442.
6. Samant R. S., Shevde L. A. 2011. Recent advances in anti-angiogenic therapy of cancer. Oncotarget. 2, 122-134.
7. Dock G. 1904. The influence of complicating diseases upon leukemia. Am. J. Med. Sci. 127, 563-592.
8. De Pace N. G. 1912. Sulla scomparsa di un enorme cancro vegetante del callo dell'utero senza cura chirurgica. Ginecologia. 9, 82-86.
9. Levaditi C., Nicolau S. 1922. Sur la culture de virus vaccinal dans les neoplasmes epitheliaux. CR Soc. Biol. 85, 928.
10. Levaditi C., Nicolau S. 1922. Affinite du virus herpetique pour les neoplasmes epitheliaux. CR Soc. Biol. 87, 498-500.
11. Levaditi C., Nicolau S. 1923. Vaccine et neoplasmes. Ann. Inst. Pasteur. 37, 443-447.
12. Suskind R. G., Huebner R. J., Rowe W. P., Love R. 1957. Viral agents oncolytic for human tumors in heterologous host; oncolytic effect of Coxsackie B viruses. Proc. Soc. Exp. Biol. Med. 94, 309-318.
13. Bluming A. Z., Ziegler J. L. 1971. Regression of Burkitt's lymphoma in association with measles infection. Lancet. 2, 105-106.
14. Sinkovics J., Horvath J. 1993. New developments in the virus therapy of cancer: A historical review. Intervirology. 36, 193-214.
15. Lindenmann J., Klein P. A. 1967. Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus. J. Exp. Med. 126, 93-108.
16. Kunin C. M. 1964. Cellular susceptibility to Enteroviruses. Bacteriol. Rev. 28, 382-390.
17. Asada T. 1974. Treatment of human cancer with mumps virus. Cancer. 34, 1907-1928.
18. Southam C. M. 1960. Present status of oncolytic virus studies. Trans. NY Acad. Sci. 22, 657-673.
19. Moore A. E. 1952. Viruses with oncolytic properties and their adaptation to tumors. Ann. NY Acad. Sci. 54, 945-952.
20. Moore A. E. 1954. Effects of viruses on tumors. Annu. Rev. Microbiol. 8, 393-410.
21. Newman W., Southam C. M. 1954. Virus treatment in advanced cancer A pathological study of fifty-seven cases. Cancer. 7, 106-118.
22. Voroshilova M. K., Chumakov M. P., Koroleva G. A., Grachev V. P., Lavrova I. K., Alpatova G. A., Umanskii K. G., Vaganova N. T., Rozenbaum G. I., Chartseva V. F., Rabinovich E. A., Sinyak L. I., Lukina V. A., Chichel'nitskii D. I., 1969. Continued observations on the safety and oncolytic activity of some enterovirus vaccines administered in massive dosage to patients with oncological diseases. In: Virusnyi onkoliz i iskusstvennaya geterogenizatsiya opukholei (Viral Oncolysis and Artificial Heterogenization of Tumors). Riga, p. 69.
23. Kuruppu D., Tanabe K. K. 2005. Viral oncolysis by herpes simplex virus and other viruses. Cancer Biol. Ther. 4, 524-531.
24. Everts B., van der Poel H. G. 2005. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther. 12, 141-161.
25. Power A. T., Bell J. C. 2008. Taming the Trojan horse: Optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy. Gene Ther. 15, 772-779.
26. Verheije M. H., Rottier J. M. 2012. Retargeting of viruses to generate oncolytic agents. Adv. Virol. ID 798526.
27. Mohr I. 2005. To replicate or not to replicate: Achieving selective oncolytic virus replication in cancer cells through translational control. Oncogene. 24, 7697-7709.
28. Dobbelstein M. 2004. Replicating adenoviruses in cancer therapy. Curr. Top. Microbiol. Immunol. 273, 291-334.
29. Voroshilova M. K. 1979. Enterovirusnye infektsii cheloveka (Human Enteroviral Infections). Moscow: Meditsina.
30. Pallansch M., Roos R. 2007. Enteroviruses: Polioviruses, Coxsackieviruses, Echoviruses, and newer Enteroviruses. In: Fields Virology. Eds. Knipe D. M., Howley P. M. Philadelphia: Lippincott Williams & Wilkins, pp. 840-893.
31. Flanegan J. B., Petterson R. F., Ambros V., Hewlett N. J., Baltimore D. 1977. Covalent linkage of a protein to a defined nucleotide sequence at the 5′-terminus of virion and replicative intermediate RNAs of poliovirus. Proc. Natl. Acad. Sci. U. S. A. 74, 961-965.
32. Lee Y. F., Nomoto A., Detjen B. M., Wimmer E. 1977. A protein covalently linked to poliovirus genome RNA. Proc. Natl. Acad. Sci. U. S. A. 74, 59-63.
33. Duke G. M., Osorio J. E., Palmenberg A. C. 1990. Attenuation of Mengo virus through genetic engineering of the 5′ noncoding poly(C) tract. Nature. 343, 474-476.
34. Hahn H., Palmenberg A. C. 1995. Encephalomyocarditis viruses with short poly(C) tracts are more virulent than their mengovirus counterparts. J. Virol. 69, 2697-2699.
35. Todd S., Towner J. S., Brown D. M., Semler B. L. 1997. Replication-competent picornaviruses with complete genomic RNA 3′ noncoding region deletions. J. Virol. 71, 8868-8874.
36. Spector D. H., Baltimore D. 1974. Requirement of 3′-terminal poly(adenylic acid) for the infectivity of poliovirus RNA. Proc. Natl. Acad. Sci. U. S. A. 71, 2983-2987.
37. Jarvis T. C., Kirkegaard K. 1992. Poliovirus RNA recombination: Mechanistic studies in the absence of selection. EMBO J. 11, 3135-3145.
38. Summers D. F., Maizel J. V., Jr. 1968. Evidence for large precursor proteins in poliovirus synthesis. Proc. Natl. Acad. Sci. U. S. A. 59, 966-971.
39. Ward T., Powell R. M., Pipkin P. A., Evans D. J., Minor P. D., Almond J. W. 1998. Role for beta2-microglobulin in echovirus infection of rhabdomyosarcoma cells. J. Virol. 72, 5360-5365.
40. Shafren D. R. 1998. Viral cell entry induced by crosslinked decay-accelerating factor. J. Virol. 72, 9407-9412.
41. Shafren D. R., Dorahy D. J., Ingham R. A., Burns G. F., Barry R. D. 1997. Coxsackievirus A21 binds to decayaccelerating factor but requires intercellular adhesion molecule 1 for cell entry. J. Virol. 71, 4736-4743.
42. Bergelson J. M., Cunningham J. A., Droguett G., Kurt-Jones E. A., Krithivas A., Hong J. S., Horwitz M. S., Crowell R. L., Finberg R. W. 1997. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 275, 1320-1323.
43. Carson S. D., Chapman N. N., Tracy S. M. 1997. Purification of the putative Coxsackievirus B receptor from HeLa cells. Biochem. Biophys. Res. Commun. 233, 325-328.
44. Tomko R. P., Xu R., Philipson L. 1997. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci. U. S. A. 94, 3352-3356.
45. Mendelsohn C. L., Wimmer E., Racaniello V. R. 1989. Cellular receptor for poliovirus: Molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell. 56, 855-865.
46. Jenista J. A., Powell K. R., Menegus M. A. 1984. Epidemiology of neonatal enterovirus infection. J. Pediatr. 104, 685-690.
47. Muir P., Kämmerer U., Korn K., Mulders M. N., Pöyry T., Weissbrich B., Kandolf R., Cleator G. M., van Loon A. M. 1998. Molecular typing of enteroviruses: Current status and future requirements. The European Union concerted action on virus meningitis and encephalitis. Clin. Microbiol. Rev. 11, 202-227.
48. Lashkevich V. A., Koroleva G. A., Lukashev A. N., Denisova E. V., Katargina L. A. 2004. Enterovirus uveitis. Rev. Med. Virol. 14, 241-254.
49. Lukashev A. N., Lashkevich V. A., Koroleva G. A., Ilonen J., Karganova G. G., Reznik V. I., Hinkkanen A. E. 2003. Molecular epidemiology of enteroviruses causing uveitis and multisystem hemorrhagic disease of infants. Virology. 307, 45-53.
50. el-Sageyer M. M., Szendröi A., Hütter E., Uj M., Szücs G., Mezey I., Tóth I., Kátai A., Kapiller Z., Páll G., Petrás G., Szalay E., Mihály I., Gourova S., Berencsi G. 1998. Characterisation of an echovirus type 11' (prime) epidemic strain causing haemorrhagic syndrome in newborn babies in Hungary. Acta Virol. 42, 157-166.
51. Rabkin C. S., Telzak E. E., Ho M. S., Goldstein J., Bolton Y., Pallansch M., Anderson L., Kilchevsky E., Solomon S., Martone W. J. 1988. Outbreak of echovirus 11 infection in hospitalized neonates. Pediatr. Infect. Dis. J. 7, 186-190.
52. Voroshilova M. K. 1989. Potential use of nonpathogenic enteroviruses for control of human disease. Prog. Med. Virol. 36, 191-202.
53. Voroshilova M. K. 1988. Virological and immunological aspects of administration of live enteroviral vaccines in oncological diseases. In: Poleznye dlya ogranizma nepatogennye shtammy enterovirusov: profilakticheskoe i lechebnoe ikh primenenie (Useful Nonpathogenic Enterovirus Strains: Preventive and Therapeutic Applications). Moscow: Meditsina, pp. 24-29.
54. Voroshilova M. K. 1977. Evolution of enteroviral infections. Vestn. Akad. Med. Nauk SSSR. 42-50.
55. Au G. G., Beagley L. G., Haley E. S., Barry R. D., Shafren D. R. 2011. Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18. Virol. J. 8, 22.
56. Taylor M. W., Cordell B., Souhrada M., Prather S. 1971. Viruses as an aid to cancer therapy: Regression of solid and ascites tumors in rodents after treatment with bovine enterovirus. Proc. Natl. Acad. Sci. U. S. A. 68, 836-840.
57. Berry L. J., Au G. G., Barry R. D., Shafren D. R. 2008. Potent oncolytic activity of human enteroviruses against human prostate cancer. Prostate. 68, 577-587.
58. Haley E. S., Au G. G., Carlton B. R., Barry R. D., Shafren D. R. 2009. Regional administration of oncolytic echovirus 1 as a novel therapy for the peritoneal dissemination of gastric cancer. J. Mol. Med. 87, 385-399.
59. Muceniece A. J. 1978. Analysis of sensitivity of human melanomas to enteroviruses adaptred to these tumors. In: Virusy v terapii opukholei (Viruses in Antitumor Therapy), Riga: Zinatne, pp. 175-189.
60. Dobrikova E. Y., Broadt T., Poiley-Nelson J., Yang X., Soman G., Giardina S., Harris R., Gromeier M. 2008. Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype. Mol. Ther. 16, 1865-1872.
61. Gromeier M., Lachmann S., Rosenfeld M. R., Gutin P. H., Wimmer E. 2000. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc. Natl. Acad. Sci. U. S. A. 97, 6803-6808.
62. Toyoda H., Ido M., Hayashi T., Gabazza E. C., Suzuki K., Kisenge R. R., Kang J., Hori H., Komada Y. 2004. Experimental treatment of human neuroblastoma using live-attenuated poliovirus. Int. J. Oncol. 24, 49-58.
63. Toyoda H., Wimmer E., Cello J. 2011. Oncolytic poliovirus therapy and immunization with poliovirusinfected cell lysate induces potent antitumor immunity against neuroblastoma in vivo. Int. J. Oncol. 38, 81-87.
64. Au G. G., Lincz L. F., Enno A., Shafren D. R. 2007. Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. Br. J. Haematol. 137, 133-141.
65. Au G. G., Lindberg A. M., Barry R. D., Shafren D. R. 2005. Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21. Int. J. Oncol. 26, 1471-1476.
66. Skelding K. A., Barry R. D., Shafren D. R. 2009. Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21. Breast Cancer Res. Treat. 113, 21-30.
67. Chumakov M. P., Voroshilova M. K., Antsupova A. S., Boiko V. M., Blinova M. I., Priimyagi L. S., Rodin V. I., Seibil' V. B., Sinyak K. M., Smorodintsev A. A., Stepanchuk V. A., Terekhov S. N., Trofimova L. I., Chumakov P. M. 1992. Live enteroviral vaccines for urgent preventive therapy against respiratory diseases during autumn-winter epidemics of influenza and acute respiratory diseases. Zh. Mikrobiol. Epidemiol. Infekts. Dis. 37-40.
68. Voroshilova M. K., Tol'skaya E. A., Koroleva G. A., Chumakov K. M., Chumakov, P. M. 1970. Studies on biological and morphological properties of viruses ECHO-1 and ECHO-12. In: Enterovirusnye infektsii (Enteroviral Infections). Tr. Inst. Poliom. Virus. Entsef. Akad. Med. Nauk SSSR. Moscow, pp. 269-274.
69. Koroleva G. A., Voroshilova M. K., Grachev V. P. 1969. Biological properties of enteroviral vaccine strains ZhEV-4, ZhEV-7, ZhEV11, and ZhEV-13. Materialy 16 nauchnoi sessii instituta poliomielita i virusnykh entsefalitov (Proc. 16th Sci. Session of the Institute of Poliomyelitis and Viral Encephalitides), Moscow, p. 185.
70. Chumakov M. P., Voroshilova M. K., Boiko V. M. 1973. On the results of large-scale controlled trials for epidemiological efficiency of live enterovirus vaccines for urgent preventive treatment against influenza and viral acute respiratory diseases. Tr. Inst. Poliom. Virus. Entsef. Akad. Med. Nauk SSSR. Moscow, pp. 19-28.
71. Voroshilova M. K., Baganova N. T. 1969. Experience in treating patients with gastrointestinal tumors by live enterovirus vaccines. In: Virusnyi onkoliz i iskusstvennaya geterogenizatsiya opukholei (Viral Oncolysis and Artificial Heterogenization of Tumors). Riga, pp. 23-26.
72. Tsypkin L. B., Voroshilova M. K., Goryunova A. G., Lavrova I. K., Koroleva G. A. 1976. The morphology of tumors of the human gastrointestinal tract in shortterm organ culture and the reaction of these tumors to infection with poliovirus. Cancer. 38, 1796-1806.
73. Voroshilova M. K., Goryunova A. G., Gorbachkova E. A., Chumakov P. M., Oganyan G. R., Kodkind G. H. 1977. Studies on cellular immunity of oncological patients in the course of asymptomatic enteroviral infection. In: Virusnyi onkoliz i iskusstvennaya geterogenizatsiya opukholei (Viral Oncolysis and Artificial Heterogenization of Tumors). Riga, pp. 17-19.
74. Voroshilova M. K., Magazanik S. S., Chumakov P. M., 1980. Useful human viruses. In: Aktual'nye voprosy epidemiologii, mikrobiologii i infektsionnykh zabolevanii (Current Problems of Epidemiology, Microbiology, and Infectious Diseases), Tashkent: Meditsina, pp. 227-229.
75. Muceniece A. J. 1972. Onkotropizm virusov i problema viroterapii zlokachestvennykh opukholei (Oncotropism of Viruses and the Problem of Viral Therapy against Malignant Tumors). Riga: Zinatne.
76. Muceniece A. J., Bumbieris J. V. 1982. Transplantation antigens and their changes in carcinogenesis and viral infection. In: Virusnyi onkoliz i iskusstvennaya geterogenizatsiya opukholei (Viral Oncolysis and Artificial Heterogenization of Tumors). Riga, pp. 217-234.
77. Priedite I. J., Garklava R. R., Muceniece A. J. 1971. Treatment of patients with gastric cancer after palliative surgery. Materialy III konferentsii onkologov ESSR, LitSSR i LatvSSR (Proc. III Conf. of Estonian, Lithuanian, and Latvian Oncologists), Riga, p. 77.
78. Shafren D. R., Sylvester D., Johansson E. S., Campbell I. G., Barry R. D. 2005. Oncolysis of human ovarian cancers by echovirus type 1. Int. J. Cancer. 115, 320-328.
79. Bergelson J. M., Shepley M. P., Chan B. M., Hemler M. E., Finberg R. W. 1992. Identification of the integrin VLA-2 as a receptor for echovirus 1. Science. 255, 1718-1720.
80. King S. L., Cunningham J. A., Finberg R. W., Bergelson J. M. 1995. Echovirus 1 interaction with the isolated VLA-2 I domain. J. Virol. 69, 3237-3239.
81. Moser T. L., Pizzo S. V., Bafetti L. M., Fishman D. A., Stack M. S. 1996. Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta1 integrin. Int. J. Cancer. 67, 695-701.
82. Bartolazzi A., Kaczmarek J., Nicolo G., Risso A. M., Tarone G., Rossino P., Defilippi P., Castellani P. 1993. Localization of the alpha 3 beta 1 integrin in some common epithelial tumors of the ovary and in normal equivalents. Anticancer Res. 13, 1-11.
83. Buczek-Thomas J. A., Chen N., Hasan T. 1998. Integrin-mediated adhesion and signalling in ovarian cancer cells. Cell Signal. 10, 55-63.
84. Cannistra S. A., Ottensmeier C., Niloff J., Orta B., DiCarlo J. 1995. Expression and function of beta 1 and alpha v beta 3 integrins in ovarian cancer. Gynecol. Oncol. 58, 216-225.
85. Koike N., Todoroki T., Komano H., Shimokama T., Ban S., Ohno T., Fukao K., Watanabe T. 1997. Invasive potentials of gastric carcinoma cell lines: role of alpha 2 and alpha 6 integrins in invasion. J. Cancer Res. Clin. Oncol. 123, 310-316.
86. Jokinen J., White D. J., Salmela M., Huhtala M., Kapyla J., Sipila K., Puranen J. S., Nissinen L., Kankaanpaa P., Marjomaki V., Hyypia T., Johnson M. S., Heino J. 2010. Molecular mechanism of alpha2beta1 integrin interaction with human echovirus 1. EMBO J. 29, 196-208.
87. Bianco A., Whiteman S. C., Sethi S. K., Allen J. T., Knight R. A., Spiteri M. A. 2000. Expression of intercellular adhesion molecule-1 (ICAM-1) in nasal epithelial cells of atopic subjects: A mechanism for increased rhinovirus infection? Clin. Exp. Immunol. 121, 339-345.
88. Lublin D. M., Atkinson J. P. 1989. Decay-accelerating factor: Biochemistry, molecular biology, and function. Annu. Rev. Immunol. 7, 35-58.
89. Rosette C., Roth R. B., Oeth P., Braun A., Kammerer S., Ekblom J., Denissenko M. F. 2005. Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis. 26, 943-950.
90. Shafren D. R., Au G. G., Nguyen T., Newcombe N. G., Haley E. S., Beagley L., Johansson E. S., Hersey P., Barry R. D. 2004. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. Clin. Cancer Res. 10, 53-60.
91. Skelding K. A., Barry R. D., Shafren D. R. 2010. Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride. Invest. New Drugs. 21, 21.
92. Wodarz D. 2001. Viruses as antitumor weapons: Defining conditions for tumor remission. Cancer Res. 61, 3501-3507.
93. Mueller S., Wimmer E., Cello J. 2005. Poliovirus and poliomyelitis: A tale of guts, brains, and an accidental event. Virus Res. 111, 175-193.
94. Dobrikova E., Florez P., Bradrick S., Gromeier M. 2003. Activity of a type 1 picornavirus internal ribosomal entry site is determined by sequences within the 3′ nontranslated region. Proc. Natl. Acad. Sci. U. S. A. 100, 15125-15130.
95. Toyoda H., Yin J., Mueller S., Wimmer E., Cello J. 2007. Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirussusceptible animal model. Cancer Res. 67, 2857-2864.
96. Gromeier M., Solecki D., Patel D. D., Wimmer E. 2000. Expression of the human poliovirus receptor/CD155 gene during development of the central nervous system: implications for the pathogenesis of poliomyelitis. Virology. 273, 248-257.
97. Solecki D., Bernhardt G., Lipp M., Wimmer E. 2000. Identification of a nuclear respiratory factor-1 binding site within the core promoter of the human polio virus receptor/CD155 gene. J. Biol. Chem. 275, 12453-12462.
98. Solecki D., Wimmer E., Lipp M., Bernhardt G. 1999. Identification and characterization of the cis-acting elements of the human CD155 gene core promoter. J. Biol. Chem. 274, 1791-1800.
99. Solecki D. J., Gromeier M., Mueller S., Bernhardt G., Wimmer E. 2002. Expression of the human poliovirus receptor/CD155 gene is activated by sonic hedgehog. J. Biol. Chem. 277, 25697-25702.
100. Ochiai H., Moore S. A., Archer G. E., Okamura T., Chewning T. A., Marks J. R., Sampson J. H., Gromeier M. 2004. Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus. Clin. Cancer Res. 10, 4831-4838.
101. Ansardi D. C., Porter D. C., Anderson M. J., Morrow C. D. 1996. Poliovirus assembly and encapsidation of genomic RNA. Adv. Virus Res. 46, 1-68.
102. Ansardi D. C., Porter D. C., Jackson C. A., Gillespie G. Y., Morrow C. D. 2001. RNA replicons derived from poliovirus are directly oncolytic for human tumor cells of diverse origins. Cancer Res. 61, 8470-8479.
103. Porter D. C., Ansardi D. C., Morrow C. D. 1995. Encapsidation of poliovirus replicons encoding the complete human immunodeficiency virus type 1 gag gene by using a complementation system which provides the P1 capsid protein in trans. J. Virol. 69, 1548-1555.
104. Porter D. C., Melsen L. R., Compans R. W., Morrow C. D. 1996. Release of virus-like particles from cells infected with poliovirus replicons which express human immunodeficiency virus type 1 Gag. J. Virol. 70, 2643-2649.
105. Solecki D., Schwarz S., Wimmer E., Lipp M., Bernhardt G. 1997. The promoters for human and monkey poliovirus receptors: Requirements for basic and cell type-specific activity. J. Biol. Chem. 272, 5579-5586.
106. Goetz C., Gromeier M. 2010. Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme. Cytokine Growth Factor Rev. 21, 197-203.
107. Merrill M. K., Dobrikova E. Y., Gromeier M. 2006. Cell-type-specific repression of internal ribosome entry site activity by double-stranded RNA-binding protein 76. J. Virol. 80, 3147-3156.
108. Merrill M. K., Gromeier M. 2006. The doublestranded RNA binding protein 76: NF45 heterodimer inhibits translation initiation at the rhinovirus type 2 internal ribosome entry site. J. Virol. 80, 6936-6942.
109. Ochiai H., Campbell S. A., Archer G. E., Chewning T. A., Dragunsky E., Ivanov A., Gromeier M., Sampson J. H. 2006. Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus. Clin. Cancer Res. 12, 1349-1354.
110. De Jesus N., Franco D., Paul A., Wimmer E., Cello J. 2005. Mutation of a single conserved nucleotide between the cloverleaf and internal ribosome entry site attenuates poliovirus neurovirulence. J. Virol. 79, 14235-14243.
111. Paul A. V. 2002. Possible unifying mechanism of picornavirus genome replication. In: Molecular Biology of Picornaviruses. Eds. Semler B. L., Wimmer E. Washington, DC: ASM Press, pp. 227-246.
112. Yin J., Paul A. V., Wimmer E., Rieder E. 2003. Functional dissection of a poliovirus cis-acting replication element [PV-cre(2C)]: Analysis of single- and dualcre viral genomes and proteins that bind specifically to PV-cre RNA. J. Virol. 77, 5152-5166.
113. Coffey M. C., Strong J. E., Forsyth P. A., Lee P. W. 1998. Reovirus therapy of tumors with activated Ras pathway. Science. 282, 1332-1334.
114. Nakamura H., Kasuya H., Mullen J. T., Yoon S. S., Pawlik T. M., Chandrasekhar S., Donahue J. M., Chiocca E. A., Chung R. Y., Tanabe K. K. 2002. Regulation of herpes simplex virus gamma(1)34. 5 expression and oncolysis of diffuse liver metastases by Myb34. 5. J. Clin. Invest. 109, 871-882.
115. Nemunaitis J., Ganly I., Khuri F., Arseneau J., Kuhn J., McCarty T., Landers S., Maples P., Romel L., Randlev B., Reid T., Kaye S., Kirn D. 2000. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res. 60, 6359-6366.